Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 9/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6422780 | 0.90 | HDAC1 (0.52) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL9903966 | 0.84 | CA1 (0.65) | HTR2CHTR2AKDM4EMAPK1HSD17B10 | |
| SCHEMBL3242063 | 0.78 | HTR2A (0.61) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL6038295 | 0.78 | CA1 (0.66) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL7454059 | 0.77 | KDM4E (0.67) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL6474408 | 0.77 | KDM4E (0.62) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL6474168 | 0.77 | KDM4E (0.62) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL10650585 | 0.77 | KMT2A (0.37) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| SCHEMBL2187576 | 0.76 | HDAC1 (0.55) | HTR2CHTR2AKDM4EALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL6484333 | 0.75 | KDM4E (0.71) | HTR2CHTR2AKDM4EALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030109-B2 | 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA & UPJOHN COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| US-20050282796-A1 | Tetracyclic azepinoindole compounds | PFIZER | 2005-12-22 | — | — | US | disclosed |
| EP-1351961-B1 | SUBSTITUTED INDOLINES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN CO LLC (US) | 2005-07-27 | — | — | EP | disclosed |
| US-6921823-B2 | 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-07-26 | — | — | US | disclosed |
| US-6903090-B2 | Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal | PFIZER (US) | 2005-06-07 | — | — | US | disclosed |
| EP-1196417-B1 | 1,2,3,4,5,6-HEXAHYDROAZEPINO 4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | UPJOHN CO (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6878823-B2 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA & UPJOHN COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-6875762-B2 | Tetracyclic azepinoindole compounds | PFIZER (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040248880-A1 | 1,2,3,4,5,6-Hexahydroazepino[4,5-B]indoles containing arylsulfones at the 9-position | JACOBSEN ERIC JON (US) | 2004-12-09 | — | — | US | disclosed |
| US-6828314-B2 | Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity | PFIZER | 2004-12-07 | — | — | US | disclosed |
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | disclosed |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2002-06-20 | — | — | US | disclosed |
| US-6407092-B1 | 5-HYDROXYTRYPTAMINE MODULATORS AND ANTISEROTONINE AGENTS; TREATING EATING, SEXUAL, SLEEP, NERVOUS SYSTEM, PSYCHOLOGICAL, AND GASTROINTESTINAL DISORDERS; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | PHARMACIA & UPJOHN COMPANY | 2002-06-18 | — | — | US | disclosed |
| WO-2002024701-A2 | SUBSTITUTED AZEPINO[4,5B)INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002024700-A2 | SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
| US-20020022616-A1 | Azepino[4,5-b]pyrano[3,2-e]indoles | PHARMACIA & UPJOHN COMPANY | 2002-02-21 | — | — | US | disclosed |
| EP-1173440-A1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2002004456-A1 | SUBSTITUTED 2,3,7,8,9,10,11,12-OCTAHYDROAZEPINO[4,5-b]PYRANO[3,2-e]INDOLES | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004457-A1 | AZEPINO[4,5-B]PYRANO[3,2-E]INDOLES | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2000064899-A1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | HTR2C 5/4885HTR2A 11/4885KDM4E 1122/4885 |
| US-20050282796-A1 | Tetracyclic azepinoindole compounds | TBXA2R, NPY5R, AZI2 | HTR2C 22/4885HTR2A 34/4885KDM4E 1036/4885 |
| US-20040248880-A1 | 1,2,3,4,5,6-Hexahydroazepino[4,5-B]indoles containing arylsulfones at the 9-position | TPH1, HTR1A, HTR1D | HTR2C 21/4885HTR2A 44/4885KDM4E 1239/4885 |
| US-20020022616-A1 | Azepino[4,5-b]pyrano[3,2-e]indoles | NPY5R, HTR3C, HTR5A | HTR2C 74/4885HTR2A 175/4885KDM4E 451/4885 |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | HTR5A, HTR1A, HTR4 | HTR2C 6/4885HTR2A 9/4885KDM4E 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.